# Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer

> **NCT00086827** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 36 (actual)

## Conditions studied

- Recurrent Small Cell Lung Cancer

## Interventions

- **DRUG:** romidepsin
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00086827
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2006-11
- **Final completion:** —
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2014-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00086827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00086827, "Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00086827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*